Disability progression in a clinical trial of relapsing-remitting multiple sclerosis eight-year follow-up

Archives of Neurology

Volumn 67, Issue 11, 2010, Pages 1329-1335

  Rudick, Richard A ^a   Lee, Jar Chi ^a   Cutter, Gary R ^b   Miller, Deborah M ^a   Bourdette, Dennis ^c   Weinstock Guttman, Bianca ^d   Hyde, Robert ^e   Zhang, Hao ^e   You, Xiaojun ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d JACOBS NEUROLOGICAL INSTITUTE   (United States)

^e BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; PLACEBO;

ADULT; AMBULATORY CARE; ARTICLE; CLINICAL EVALUATION; CLINICAL RESEARCH; CLINICAL STUDY; CONTROLLED STUDY; DISABILITY SEVERITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE SCLEROSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

DISABILITY EVALUATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; LOGISTIC MODELS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 77954891546     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.150     Document Type: Article

References (22)

1. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343(20):1430-1438.
2. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(pt 3):606-616. (Pubitemid 43278223)
3. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain. 1980;103(2):281-300.
4. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study, 2: predictive value of the early clinical course. Brain. 1989;112(pt 6):1419-1428. (Pubitemid 20024212)
5. Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis. Arch Neurol. 2006;63(12):1686-1691. (Pubitemid 44925075)
6. Ellison GW, Myers LW, Leake BD, et al; Cyclosporine Multiple Sclerosis Study Group. Design strategies in multiple sclerosis clinical trials. Ann Neurol. 1994;36(suppl):S108-S112.
7. Butzkueven H, Mechati S, Hoffman MW, et al. Trial-defined disease progression in multiple sclerosis is a poor measure of permanent disability progression. Neurology. 2007;68(suppl 1):A165.
8. Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH. Disability as an outcome in MS clinical trials. Neurology. 2008;71(9):624-631.
9. Jacobs LD, Cookfair DL, Rudick RA, et al; The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39(3):285-294.
10. Rudick RA, Cutter GR, Baier M, et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult Scler. 2005;11(6):626-634.
11. Jacobs LD, Cookfair DL, Rudick RA, et al; The Multiple Sclerosis Collaborative Research Group (MSCRG). A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Mult Scler. 1995;1(2):118-135.
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452.
13. Altman DG, Bland JM. Diagnostic tests 2: predictive values. BMJ. 1994;309(6947):102.
14. Liu C, Blumhardt LB. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry. 2000;68(4):450-457.
15. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain. 1991;114(pt 2):1045-1056.
16. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003;126(pt 4):770-782. (Pubitemid 36372978)
17. Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F; LORSEP Group. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol. 2008;15(9):916-921.
18. Young PJ, Lederer C, Eder K, et al; Sylvia Lawry Centre for Multiple Sclerosis Research. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis. Neurology. 2006;67(5):804-808.
19. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon beta-1a in relapsing MS. Neurology. 2001;56(12):1628-1636.
20. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006;67(6):944-953.
21. Schwid SR, Bever CT Jr. The cost of delaying treatment multiple sclerosis: what is lost is not regained. Neurology. 2001;56(12):1620.
22. Brenner H, Gefeller O. Variation of sensitivity, specificity, likelihood ratios, and predictive values with disease prevalence. Stat Med. 1997;16(9):981-991.